News Archive

2020

May

Media Release / May 29, 2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Read More
Media Release / May 27, 2020

Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)

Read More

April

Media Release / Apr 03, 2020

Novartis and the Novartis US Foundation establish USD 5 million US COVID-19 Community Response Fund

Read More

March

Media Release / Mar 28, 2020

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 28, 2020

Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 18, 2020

Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

Read More
Media Release / Mar 18, 2020

Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements

Read More
Featured News / Mar 11, 2020

Novartis provides update on use and safety of Beovu® in patients with wet AMD

Read More

February

Scientists are working to develop drugs for individuals living with sickle cell disease
Story / Feb 24, 2020

Shaping the future of sickle cell disease

Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.

Read More
Featured News / Feb 12, 2020

Novartis launches new Preferred Firm Program for legal services

Read More

Related Links